OncLive Peer Exchange®

In this OncLive® Peer Exchange, moderator Zev Wainberg, MD, MSc (David Geffen School of Medicine at UCLA, Santa Monica, CA) is joined by panelists Elena Elimova, MD (Princess Margaret Cancer Centre, Toronto, ON); Manish A. Shah, MD (Weill Cornell Medicine, New York, NY); and Raj Shameem, MD (Orlando Health Cancer Institute, Orlando, FL) for a discussion on evolving first-line treatment strategies in HER2-positive metastatic gastroesophageal adenocarcinoma (GEA). The panel unpacks the phase 3 HERIZON-GEA-01 trial of zanidatamab plus chemotherapy and zanidatamab plus tislelizumab plus chemotherapy versus trastuzumab plus chemotherapy, addressing the biparatopic mechanism of zanidatamab, interpretation of PD-L1 tumor area positivity (TAP) and combined positive score (CPS) data, HER2 heterogeneity and retesting at progression, proactive diarrhea prophylaxis, second-line sequencing with trastuzumab deruxtecan (T-DXd), upcoming trials (ARTEMIDE-Gastric01, DESTINY-Gastric05, HLX22), and patient-facing conversations. Tailored for community and academic oncologists, board-certified oncology pharmacists (BCOPs), and multidisciplinary oncology care teams.

In this OncLive Peer Exchange filmed live at SGO 2026 in San Juan, Puerto Rico, Robert M. Wenham, MD, MS is joined by Premal H. Thaker, MD, MS, Tiffany M. Redfern, MD, FACOG, and Gottfried E. Konecny, MD, for an expert discussion on practice-changing advances in endometrial cancer, including long-term RUBY trial data, biomarker-driven treatment selection, real-world evidence, second-line sequencing, and the future of immunotherapy and targeted therapy in this rapidly evolving field.

Expert faculty examine the evolving role of antibody-drug conjugates in endometrial, ovarian, and cervical cancers, with discussion focused on biomarker-driven treatment selection, sequencing strategies, toxicity management, and emerging targets poised to further reshape care.

In this OncLive Peer Exchange, Dr. Mohamed Abdelbaki (Washington University, St. Louis) moderates a panel with Dr. Susan Chi (Dana-Farber Cancer Institute), Dr. Murali Chintagumpala (Texas Children's, Houston), and Dr. Ashley Margol (Children's Hospital Los Angeles) on treatment decision-making in pediatric low-grade glioma (PLGG).

The panel of experts will explore opportunities for how circulating tumor DNA and molecular residual disease testing are reshaping risk assessment and treatment decision-making across genitourinary malignancies, with a primary focus on muscle-invasive bladder cancer. They will discuss how emerging molecular data informs response evaluation, sequencing strategies, escalation and de-escalation decisions, and the evolving role of liquid biopsy in real-world clinical practice.

This expert-led oncology program features Dr. Hope Rugo, Dr. Aaron Lisberg, Dr. Neel Pasricha, Dr. Sarah Sunshine, Liz Castronovo, NP, and Stephanie McDonald, NP, who provide a clinically focused discussion on adverse events associated with antibody–drug conjugates (ADCs) in breast and lung cancer. The discussion synthesizes emerging clinical trial data and real‑world experience to guide frontline clinicians in preventing, identifying, and managing key toxicities. Dr. Lisberg outlines pulmonary risk assessment and ILD monitoring strategies. Dr. Rugo provides breast cancer–specific risk considerations and treatment‑modification guidance. NPs Castronovo and McDonald emphasize patient education, symptom triage, and practical toxicity‑management workflows. Drs. Sunshine and Pasricha explain ocular toxicity mechanisms, evaluation, and coordination between oncology and ophthalmology.

Key themes include proactive monitoring, multidisciplinary collaboration, patient‑centered education, and personalized dose‑modification strategies. The program is designed to support oncology clinicians in translating evolving ADC safety data into evidence‑based clinical practice.

This OncLive Peer Exchange featured Drs. Julia Rotow, Ticiana Leal, Estelamari Rodriguez, and Ignacio Wistuba discussing optimal care strategies for patients with ROS1-positive non-small cell lung cancer. Key topics included comprehensive testing importance incorporating DNA and RNA next-generation sequencing to avoid missing actionable fusions, understanding that circulating tumor DNA serves as a useful adjunct but cannot replace tissue-based testing for definitive diagnosis.

The discussion highlighted significant therapeutic evolution from first-generation agents like crizotinib with limited central nervous system activity to modern selective inhibitors like taletrectinib offering remarkable durability with progression-free survival exceeding 45 months. Central nervous system activity emerged as critical, allowing systemic therapy to replace radiation in many patients and significantly impacting long-term outcomes.

Safety profiles differ substantially between agents, requiring clinician familiarity with unique toxicity patterns for optimal patient management. The panelists emphasized that while ROS1 fusions are rare, occurring in 1% to 2% of patients with non-small cell lung cancer, identifying these alterations transforms patient outcomes with potential for sustained disease control and excellent quality of life lasting many years.

Panelists discuss the evolving management of metastatic castration-sensitive prostate cancer, with a focus on how patient complexity, long-term survivorship, and emerging evidence are shaping treatment intensification strategies. They explore practical considerations that inform selection of androgen receptor pathway inhibitors, review data from both clinical trials and real-world studies, and share perspectives on optimizing tolerability and quality of life in everyday practice.

Evolving Treatment Sequencing and Practical Management in Advanced Renal Cell Carcinoma features expert discussion led by Dr. Sumanta (Monty) Kumar Pal, with insights from Ulka N. Vaishampayan, MD; Vincent Xu, MD; Alan Tan, MD; and Matthew T. Campbell, MD. Together, the panel examines how advanced RCC is managed across the disease continuum, from risk stratified frontline decision making and evolving adjuvant strategies to second line sequencing. The program emphasizes real world interpretation of progression, thoughtful integration of newer regimens, and practical toxicity management to support individualized, long term patient care.

In this OncLive Peer Exchange, Richard F. Riedel, MD; Jason Sicklick, MD; and Kathleen Polson, NP, discuss contemporary multidisciplinary management of desmoid tumor across the full care continuum. The panel explores evolving referral patterns, diagnostic confirmation, and the clinical implications of molecular findings, while highlighting the shift away from routine upfront surgery toward observation and systemic therapy when appropriate. They examine how patient reported outcomes influence treatment thresholds, outline strategies for managing therapy-related adverse events, and address fertility and reproductive counseling considerations in younger patients. Emphasizing structured multidisciplinary collaboration and individualized decision making, the discussion underscores how integrating tumor biology, symptom burden, and patient priorities can improve coordination of care and optimize outcomes in desmoid tumor management.

This program explored the evolving landscape of HER2-targeted therapies, highlighting recent clinical trial data, real-world implementation, and patient-centered care. Experts discussed guideline-driven treatment decision-making, emphasizing NCCN recommendations as a foundation while accounting for individual patient characteristics, comorbidities, and treatment setting. Strategies for managing therapy-related toxicities, such as interstitial lung disease, cardiotoxicity, ocular, and gastrointestinal effects, were highlighted, with an emphasis on proactive monitoring, patient education, and multidisciplinary collaboration with cardiologists, pulmonologists, neurologists, nurses, and pharmacists. Survivorship planning was emphasized for long-term quality of life, including restoring patient autonomy and addressing persistent side effects. Equitable access to novel therapies was explored, addressing financial toxicity, biomarker testing, infusion logistics, and community-based adoption. Finally, the program discussed the importance of ongoing clinician education, digital resources, and patient engagement, reflecting a rapidly evolving field that balances cutting-edge science with practical, patient-centered implementation across diverse practice settings.

This program provides a comprehensive overview of the rapidly evolving landscape of colorectal cancer (CRC) care, highlighting recent advances in biomarkers, targeted therapies, and circulating tumor DNA (ctDNA) applications. Experts discuss the latest clinical trial data, including new therapeutic options in the refractory metastatic setting, offering insights into the nuances of efficacy, tolerability, and patient selection. The conversation also explores the expanding role of ctDNA in detecting minimal residual disease (MRD), guiding adjuvant therapy decisions, and informing surveillance strategies, while addressing the challenges of assay variability, interpretation, and clinical implementation. Throughout the program, the panel emphasizes the importance of individualized, data-driven decision-making, the evolving nature of clinical tools, and the potential for novel approaches to improve patient outcomes. Listeners gain both a detailed understanding of current evidence and a forward-looking perspective on innovations poised to shape CRC management.

This OncLive Peer Exchange program features expert discussion on the evolving management of metastatic pancreatic ductal adenocarcinoma. Faculty compare Nalirifox and FOLFIRINOX using clinical trial and real world evidence, address practical considerations in treatment delivery and toxicity management, and explore sequencing strategies and future therapeutic approaches. The program provides actionable insights to support individualized, evidence based care in everyday oncology practice.

This educational activity covers important updates in triple-negative breast cancer (TNBC). Expert faculty discuss recent developments in both early-stage and metastatic TNBC. Clinical trial data with antibody-drug conjugates are explored by breast oncologists. Important takeaways from the clinical trials and how they will carry over into clinical practice are assessed.

This comprehensive panel discussion explored contemporary and emerging treatment strategies for acute myeloid leukemia (AML), focusing on the expanding role of targeted therapies, optimized venetoclax-based regimens, menin inhibitors, triplet combinations, transplant sequencing, and real-world implementation challenges. Experts examined how genomic profiling, disease biology, and patient fitness increasingly dictate individualized therapy selection. They reviewed data from early-phase studies, retrospective analyses, and large cooperative group trials, highlighting how improved tolerability and deeper remissions are reshaping frontline and relapsed AML management. Special emphasis was placed on understanding how molecular subsets, such as KMT2A rearrangements, NPM1 mutations, TP53 mutations, RAS-pathway lesions, and secondary-type mutations, respond to novel agents. Discussions also addressed outpatient monitoring, mitigating toxicity, evolving measurable residual disease (MRD)-driven strategies, and ongoing phase 3 trials that could shift standards of care. Overall, the program discusses a rapidly accelerating transition toward biology-driven, less intensive regimens.

This program offers an in-depth, expert-driven exploration of the evolving treatment landscape for chronic lymphocytic leukemia (CLL), highlighting how targeted therapies are reshaping standards of care across frontline, relapsed, and refractory settings. Through panel discussion and analysis, leading clinicians examine the roles of covalent and non-covalent BTK inhibitors, venetoclax-based regimens, and the recently FDA-approved pirtobrutinib. The panel reviews emerging evidence for sequencing therapies, monitoring resistance, and incorporating time-limited approaches, as well as how patient-specific factors such as age, frailty, comorbidities, cytogenetics, and treatment history guide decision-making. Special emphasis is placed on real-world outcomes, retreatment considerations, MRD-guided strategies, and the future integration of cellular therapies, bispecific antibodies, and BTK degraders. The session also highlights practical co-management strategies between academic and community clinicians and identifies high-priority unmet needs, including Richter’s transformation and later-line therapeutic innovation.

Panelists discuss the role of ADCs in solid tumor care, explore the ocular adverse events associated with these agents, and discuss best practices for monitoring and managing ocular toxicities in clinical practice.

Panelists discuss modern multidisciplinary strategies in neuroendocrine tumors, with a focus on evolving guidelines, immunotherapy, and patient-centered care.

• Explore the current treatment landscape of muscle-invasive bladder cancer
• Examine the emerging role of ctDNA and MRD testing in bladder cancer disease monitoring and treatment selection
• Discuss strategies for implementing novel testing approaches into clinical practice

Panelists discuss the evolving multidisciplinary management of cutaneous squamous cell carcinoma, emphasizing diagnostic precision, timely referral, and the expanding role of immunotherapy and coordinated care in improving outcomes for high-risk and advanced disease.

Panelists discuss the evolving management of advanced and metastatic non–small cell lung cancer driven by key oncogenic alterations, emphasizing advancements in molecular diagnostics, targeted treatment development, resistance mechanisms, and personalized sequencing strategies that continue to redefine the modern standard of care.

Panelists are going to discuss recent updates in the treatment of breast cancer, focusing on the key updates for HER2-targeting therapies. We will discuss the data in the context of the evolving landscape and its impact on clinical practice.

Experts discuss the multidisciplinary management of diffuse midline glioma with H3K27M mutation, addressing the unique challenges faced by community oncologists and exploring emerging therapies aimed at improving outcomes for this aggressive tumor.

Funding support provided by Chimerix/Jazz Pharmaceuticals. Content independently developed and published by OncLive.

Panelists discuss how comprehensive biomarker testing is essential for all patients with early-stage non–small cell lung cancer, with thoracic specialists emphasizing the importance of testing primary tumor samples and lymph nodes to identify actionable mutations that guide treatment decisions and inform patients about their therapeutic journey, particularly as targeted therapies and immunotherapies continue to advance in early-stage and locally advanced disease settings.

Panelists discuss how durvalumab consolidation has become standard of care for limited-stage small cell lung cancer following the ADRIATIC trial while emphasizing the importance of ensuring all eligible patients receive first-line immunotherapy in extensive-stage disease, managing emerging toxicities like pneumonitis through multidisciplinary collaboration, implementing novel therapies such as tarlatamab with appropriate infrastructure and patient selection, and optimizing sequencing strategies for the expanding arsenal of treatments including antibody-drug conjugates, T-cell engagers, and investigational agents that are transforming the previously limited therapeutic landscape of this aggressive malignancy.

Experts explore the current frontline treatment options for EGFR-targeted therapy, examine when combination therapy may be preferred, and discuss the importance of appropriately sequencing therapies for our patients.

Panelists discuss the limitations of conventional IHC in assessing TROP2 expression, the advantages of Quantitative Continuous Scoring (QCS) in improving detection accuracy, emerging clinical data supporting TROP2 NMR as a predictive biomarker for Dato-DXd, and future considerations for integrating these tools into patient selection and treatment strategies.

Callie Coombs, MD; Nicole Lamanna, MD; Sameer A. Parikh, MBBS; Joanna M. Rhodes, MD, MSCE; and Mazyar Shadman, MD, MPH, discuss how to optimize chronic lymphocytic leukemia (CLL) treatment by incorporating prognostic biomarkers like TP53 status and IGHV mutation testing into therapy selection, weighing the benefits of continuous Bruton tyrosine kinase inhibitor therapy vs fixed-duration oral doublet regimens, managing treatment toxicities and resistance patterns, and sequencing therapies in the relapsed/refractory setting based on emerging clinical trial data presented at the European Hematology Association 2025 Congress (EHA 2025).

Sagar Lonial, MD, FACP, FASCO; Adrianna Rossi, MD; Ajay K. Nooka, MD, MPH, FACP; and Cesar Rodriguez, MD, discuss how evolving treatment strategies in multiple myeloma are shifting toward quadruplet therapy regimens for newly diagnosed patients, with CAR T-cell therapy being used increasingly in earlier lines of treatment for high-risk disease. They emphasize the importance of achieving MRD negativity and personalizing treatment approaches based on patient fitness rather than strict transplant eligibility criteria.